Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by BLACK, C. M.
Right arrow Articles by LAURENT, G. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by BLACK, C. M.
Right arrow Articles by LAURENT, G. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1989 British Society for Rheumatology

research-article

SERUM TYPE III PROCOLLAGEN PEPTIDE CONCENTRATIONS IN SYSTEMIC SCLEROSIS AND RAYNAUD'S PHENOMENON: RELATIONSHIP TO DISEASE ACTIVITY AND DURATION

CAROL M. BLACK1,*, A. McWHIRTER*, N. K. HARRISON{dagger}, J. M. E. KIRK{dagger} and G. J. LAURENT{dagger}

*Rheumatology Unit, West Middlesex University Hospital Twickenham Road, Isleworth, Middx TW76AF
{dagger}Biochemistry Unit, Department of Thoracic Medicine, Cardiothoracic Institute, University of London Fulham Road, London SW3 6HP

Correspondence to: 1Correspondence to Dr. Black.

Serum levels of the amino-terminal type III procollagen peptide (P-3-NP) have been used as an index of collagen synthesis. Systemic sclerosis (SS) is characterized by uncontrolled production of collagen of several types. This study aimed to explore the profile of P-3-NP in patients with SS and Raynaud's phenomenon, a common forerunner of the disease.

Using a radioimmunoassay, the mean level for P-3-NP was found to be raised in SS compared with both the control (p>0.001) and Raynaud's groups (p>0.001). Analysis of serial samples from the patients with SS suggested that the P-3-NP level reflected changing clinical activity. Three groups emerged: a group with stable disease which showed a less than 20%change in P-3-NP level (mean 5.7%); a group with increasing activity which showed an increase of >20%(mean 35.8%) and a group of decreasing activity which showed a decrease of >20%(mean 33.6%). These data suggest that there is an increase in collagen metabolism in SS and that changes in P-3-NP levels may reflect the clinical course of the disease.

KEY WORDS: Systemic sclerosis, Raynaud's, Type III procollagen peptide, Disease activity


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
G Valentini, A Della Rossa, S Bombardieri, W Bencivelli, A J Silman, S D'Angelo, M M. Cerinic, J F Belch, C M Black, P Bruhlmann, et al.
European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes
Ann Rheum Dis, June 1, 2001; 60(6): 592 - 598.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
R. Istok, L. Czirjak, J. Lukac, M. Stancikova, and J. Rovensky
Increased urinary pyridinoline cross-link compounds of collagen in patients with systemic sclerosis and Raynaud's phenomenon
Rheumatology, February 1, 2001; 40(2): 140 - 146.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.